1. Ustekinumab in Hidradenitis Suppurativa: A Systematic Review and Meta-analysis
- Author
-
Masson, Rahul, Seivright, Justine, Grogan, Tristan, Atluri, Swetha, Hamzavi, Iltefat, Hogeling, Marcia, Shi, Vivian Y, and Hsiao, Jennifer L
- Subjects
Biomedical and Clinical Sciences ,Clinical Sciences ,6.1 Pharmaceuticals ,Biologic treatments ,Ustekinumab ,Hidradenitis suppurativa ,Systematic review ,Meta-analysis ,Clinical sciences - Abstract
IntroductionHidradenitis suppurativa (HS) is a frequently debilitating, inflammatory skin condition. Patients may have a limited response to adalimumab, currently the only Food and Drug Administration (FDA)-approved biologic treatment for HS. Ustekinumab is an interleukin-12/23 inhibitor that has been utilized in HS, but there is a lack of an updated systematic review on its efficacy and safety. The aim of this study is to perform a systematic review and meta-analysis of the literature on the efficacy and safety of ustekinumab for HS.MethodsIn October 2022, MEDLINE and Embase databases were searched for articles on ustekinumab in HS. Data extraction was performed on relevant articles by two reviewers. The primary study outcome was the pooled response rate of HS to ustekinumab. A fixed-effects meta-analysis was performed, and Cochran's Q statistic and I squared index were used to assess heterogeneity. Statistical significance was determined at p
- Published
- 2024